C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients

Objective: C-Reactive Protein (CRP) has emerged as an accessible measured product of inflammation. Whether systemic inflammation, a common feature of Heart Failure (HF), can be reduced by HF treatments in not well established. Sacubitril/Valsartan had prognosis benefit demonstrated in the PARADIGM-H...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cardiovasc Dis
Hlavní autoři: Valentim Goncalves, Antonio, Pereira-da-Silva, Tiago, Galrinho, Ana, Rio, Pedro, Moura Branco, Luísa, Soares, Rui, Ilhao Moreira, Rita, Cruz Ferreira, Rui
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486532/
https://ncbi.nlm.nih.gov/pubmed/32923098
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky